EDIT
Income statement / Annual
Last year (2024), Editas Medicine, Inc.'s total revenue was $32.31 M,
a decrease of 58.64% from the previous year.
In 2024, Editas Medicine, Inc.'s net income was -$237.09 M.
See Editas Medicine, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$32.31 M |
$78.12 M |
$19.71 M |
$25.54 M |
$90.73 M |
$20.53 M |
$31.94 M |
$13.73 M |
$6.05 M |
$1.63 M |
| Cost of Revenue |
$0.00
|
$6.06 M
|
$6.34 M
|
$5.05 M
|
$158.00 M
|
$96.90 M
|
$90.65 M
|
$83.16 M
|
$56.98 M
|
$18.85 M
|
| Gross Profit |
$32.31 M
|
$72.06 M
|
$13.38 M
|
$20.49 M
|
-$67.26 M
|
-$76.37 M
|
-$58.72 M
|
-$69.43 M
|
-$50.93 M
|
-$17.22 M
|
| Gross Profit Ratio |
1
|
0.92
|
0.68
|
0.8
|
-0.74
|
-3.72
|
-1.84
|
-5.06
|
-8.41
|
-10.57
|
| Research and Development Expenses |
$199.25 M
|
$177.65 M
|
$174.96 M
|
$142.51 M
|
$158.00 M
|
$96.90 M
|
$90.65 M
|
$83.16 M
|
$56.98 M
|
$18.85 M
|
| General & Administrative Expenses |
$71.99 M
|
$69.65 M
|
$70.70 M
|
$76.18 M
|
$67.58 M
|
$64.56 M
|
$55.01 M
|
$50.50 M
|
$46.26 M
|
$18.10 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$71.99 M
|
$69.65 M
|
$70.70 M
|
$76.18 M
|
$67.58 M
|
$64.56 M
|
$55.01 M
|
$50.50 M
|
$46.26 M
|
$18.10 M
|
| Other Expenses |
$12.23 M
|
-$6.06 M
|
-$6.34 M
|
-$5.05 M
|
-$158.00 M
|
-$96.90 M
|
$328.00 K
|
$587.00 K
|
-$57.00 K
|
-$37.45 M
|
| Operating Expenses |
$283.47 M
|
$241.24 M
|
$239.33 M
|
$213.64 M
|
$67.58 M
|
$64.56 M
|
$145.66 M
|
$133.66 M
|
$103.24 M
|
$36.94 M
|
| Cost And Expenses |
$283.47 M
|
$247.30 M
|
$245.66 M
|
$218.69 M
|
$225.57 M
|
$161.45 M
|
$145.66 M
|
$133.66 M
|
$103.24 M
|
$36.94 M
|
| Interest Income |
$14.06 M
|
$17.57 M
|
$5.52 M
|
$607.00 K
|
$2.61 M
|
$7.31 M
|
$3.45 M
|
$0.00
|
$62.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$978.00 K
|
$0.00
|
$143.00 K
|
| Depreciation & Amortization |
$5.81 M
|
$6.06 M
|
$6.34 M
|
$5.05 M
|
$3.96 M
|
$2.83 M
|
$3.25 M
|
$2.68 M
|
$1.20 M
|
$471.00 K
|
| EBITDA |
-$233.11 M |
-$163.12 M |
-$219.61 M |
-$188.09 M |
-$130.88 M |
-$138.09 M |
-$110.47 M |
-$116.66 M |
-$96.07 M |
-$72.29 M |
| EBITDA Ratio |
-7.21
|
-2.09
|
-11.14
|
-7.36
|
-1.44
|
-6.73
|
-3.46
|
-8.5
|
-15.87
|
-44.37
|
| Operating Income Ratio |
-7.77
|
-2.17
|
-11.46
|
-7.56
|
-1.49
|
-6.86
|
-3.56
|
-8.74
|
-16.06
|
-21.68
|
| Total Other Income/Expenses Net |
$14.06 M
|
$15.96 M
|
$5.52 M
|
$644.00 K
|
$18.86 M
|
$7.18 M
|
$3.77 M
|
-$391.00 K
|
$5.00 K
|
-$37.59 M
|
| Income Before Tax |
-$237.09 M
|
-$153.22 M
|
-$220.43 M
|
-$192.50 M
|
-$115.98 M
|
-$133.75 M
|
-$109.95 M
|
-$120.32 M
|
-$97.18 M
|
-$72.90 M
|
| Income Before Tax Ratio |
-7.34
|
-1.96
|
-11.18
|
-7.54
|
-1.28
|
-6.51
|
-3.44
|
-8.76
|
-16.06
|
-44.75
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.12 M
|
$0.00
|
$0.00
|
| Net Income |
-$237.09 M
|
-$153.22 M
|
-$220.43 M
|
-$192.50 M
|
-$115.98 M
|
-$133.75 M
|
-$109.95 M
|
-$120.32 M
|
-$97.18 M
|
-$72.90 M
|
| Net Income Ratio |
-7.34
|
-1.96
|
-11.18
|
-7.54
|
-1.28
|
-6.51
|
-3.44
|
-8.76
|
-16.06
|
-44.75
|
| EPS |
-2.88 |
-2.02 |
-3.21 |
-2.85 |
-1.98 |
-2.47 |
-2.33 |
-2.98 |
-3.02 |
-2.04 |
| EPS Diluted |
-2.88 |
-2.02 |
-3.21 |
-2.85 |
-1.98 |
-2.47 |
-2.33 |
-2.98 |
-3.02 |
-2.04 |
| Weighted Average Shares Out |
$82.34 M
|
$75.97 M
|
$68.66 M
|
$67.62 M
|
$58.61 M
|
$49.98 M
|
$47.10 M
|
$40.32 M
|
$32.22 M
|
$35.70 M
|
| Weighted Average Shares Out Diluted |
$82.34 M
|
$75.97 M
|
$68.66 M
|
$67.62 M
|
$58.61 M
|
$49.98 M
|
$47.10 M
|
$40.32 M
|
$32.22 M
|
$35.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
